Results 131 to 140 of about 8,244 (227)

Eptifibatide

Reactions weekly
Bansal AB, Sattar Y, Patel P, Jamil RT.
europepmc   +2 more sources

Impact of renal function on mortality and incidence of major adverse cardiovascular events following acute coronary syndromes [PDF]

, 2010
BACKGROUND: Renal failure patients have a dismal prognosis in the setting of acute coronary syndromes (ACS). Several studies have shown that this population is undertreated, benefiting less frequently from cardiovascular agents and interventions. The aim
António, N, Baptista, R, Freitas, M, Gonçalves, F, Gonçalves, L, Jorge, E, Lourenço, C, Monteiro, P, Monteiro, S, Providência, LA, Teixeira, R   +10 more
core  

Lytic resistance of fibrin containing red blood cells [PDF]

, 2011
Kolev, Kraszimir Nikolaev, Machovich, Raymund, Szabó, László, Sótonyi, Péter, Tenekedjiev, Kiril, Wohner, Nikolett   +5 more
core   +1 more source

CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation [PDF]

, 2003
CD40 is a 48-kDa phosphorylated transmembrane glycoprotein belonging to the TNF receptor superfamily. CD40 has been demonstrated on a range of cell types, and it has an important role in adaptive immunity and inflammation.
Callard, R.E., Inwald, D.P., Klein, N.J., McDowall, A., Peters, M.J.   +4 more
core  

PAR1 Agonists Stimulate APC-Like Endothelial Cytoprotection and Confer Resistance to Thromboinflammatory Injury [PDF]

, 2018
Stimulation of protease-activated receptor 1 (PAR1) on endothelium by activated protein C (APC) is protective in several animal models of disease, and APC has been used clinically in severe sepsis and wound healing.
Aisiku, Omozuanvbo, Ceunynck, Karen De, Chaudhry, Sharjeel A., Dockendorff, Chris, Fitch-Tewfik, Jennifer L., Flaumenhaft, Robert, Higgins, Sarah J., Ingber, Donald E., Jain, Abhishek, Parikh, Samir M., Peters, Christian G.   +10 more
core   +1 more source

A Longitudinal Analysis of Outcomes Associated with Abciximab and Eptifibatide in a Consecutive Series of 3074 Percutaneous Coronary Interventions

, 2007
Kirsten Hall Long, Henry H. Ting, Erin K. McMurtry, Ryan J. Lennon, Douglas L. Wood, David R. Holmes, Ganesh Raveendran, Charanjit S. Rihal   +7 more
openalex   +1 more source

Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients [PDF]

, 2017
Krishnaraj S. Rathod, Sotiris Antoniou, Parizad Avari, Nannan Ding, P Wright, C Knight, Arun K. Jain, Anthony Mathur, EJ Smith, Roshan Weerackody, Andrew Wragg, Daniel A. Jones   +11 more
openalex   +1 more source

Unraveling the role of the homoarginine residue in antiplatelet drug eptifibatide in binding to the αIIbβ3 integrin receptor.

Thrombosis Research, 2022
D. L. van den Kerkhof, M. Nagy, K. Wichapong, S. Brouns, D. Suylen, T. Hackeng, I. Dijkgraaf   +6 more
semanticscholar   +1 more source

C-reactive protein binds to alphaIIbbeta3. [PDF]

, 2008
C-reactive protein binds to ...
Brennan, Marian P, Chubb, Anthony J, Cox, Dermot, Grennan, S, Moriarty, Roisin D   +4 more
core  

Acute Severe Thrombocytopenia Occurring After Administration of Eptifibatide Postpones Emergent Coronary Artery Surgery [PDF]

, 2016
Brent T. Boettcher, Timothy J. Olund, Paul S. Pagel   +2 more
openalex   +1 more source